Tides of Change in Medical Cannabis Laws (W6042)-Tides of Change in Medical Cannabis Law presentation

Tides of Change in Medical Cannabis Law presentation

Pdf Summary

The document reviews 2026 changes to medical cannabis law and their implications for Georgia healthcare providers and employers.<br /><br />Federally, the Department of Justice ordered certain FDA-approved or state-licensed medical cannabis products expedited rescheduling to Schedule III. The DEA is developing licensing rules, while affected businesses may continue operating under existing licenses. Other cannabis remains subject to the standard administrative rulemaking process.<br /><br />Georgia’s SB 220, signed May 12, 2026, replaced the state’s low-THC oil program with a broader Medical Cannabis Patient Registry. It removed the terminal-illness requirement for some qualifying conditions, added lupus and inflammatory bowel disease, and changed dosage regulation to milligrams. Registering physicians must have a physical Georgia business location. Healthcare institutions may qualify as caregivers and can permit patient use on their premises, arrange purchases or delivery, or adopt policies prohibiting possession and use.<br /><br />Physicians should check their organization’s policies, review patient records or the state registry, submit certification documents and identification, and meet annual certification and reporting requirements.<br /><br />The impact on the Americans with Disabilities Act (ADA) remains uncertain. Rescheduling may mean supervised medical cannabis no longer counts as “illegal drug use” under the ADA, potentially requiring reasonable accommodations, but updated federal guidance has not been issued. Georgia law still does not require employers to accommodate cannabis use and permits written zero-tolerance policies.<br /><br />Georgia does not require drug-free workplace programs, but offers incentives to participating employers. Medical cannabis remains classified as a drug under the program, and workers’ compensation coverage for prescribed cannabis is unclear; working while impaired is not permitted.<br /><br />Employers—especially federal contractors and recipients of federal funds—should proceed cautiously. Rescheduling does not prohibit zero-tolerance policies. Because cannabis may remain detectable after use, the document notes that blood testing or evidence of on-duty impairment may be more relevant than urine-test results when assessing workplace use.

Keywords

medical cannabis law

Georgia healthcare providers

employer policies

DEA rescheduling

Schedule III

Medical Cannabis Patient Registry

SB 220

ADA accommodations

zero-tolerance policies

drug testing